Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Allen Nissenson, MD has been a director since June 2020. ... Dr. Nissenson has served as Emeritus Chief Medical Officer of DaVita Kidney Care ... He is the immediate past Chair of Kidney Care Partners and immediate past Co-Chair of the Kidney Care Quality Alliance. ... We believe Dr. Nissenson’s expertise in the renal health space and extensive experience as both a public company executive, clinician and professor, qualify him for service as a director of our Company. |
| 2022-04-08 | Allen Nissenson, MD(3) 75 Director (3) Member of the Governance and Nominating Committee. 2021 Director Compensation: Fees Earned or Paid in cash ($) 68,034, Restricted Stock Unit Awards ($) 44,915, Option Awards ($) 42,319, Total ($) 155,268. |
| 2023-04-17 | Allen Nissenson, MD has been a director since June 2020. Dr. Nissenson served as Emeritus Chief Medical Officer of DaVita Kidney Care, a division of DaVita HealthCare Partners, a healthcare company, from January 2020 to January 2022. He previously served as Chief Medical Officer of DaVita Kidney Care from August 2008 to December 2019. Dr. Nissenson is also currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, a public research university, where he previously served as Director of the Dialysis Program and Associate Dean. He has served on the board of directors of Angion Biomedica Corp., a late-stage biopharmaceutical company, since January 2020. He is the immediate past Chair of Kidney Care Partners and immediate past Co-Chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. Dr. Nissenson earned his B.S. from Northwestern University and his M.D. from Northwestern University Medical School. We believe Dr. Nissenson’s expertise in the renal health space and extensive experience as both a public company executive, clinician and professor, qualify him for service as a director of our Company. |
| 2024-04-15 | Allen Nissenson, MD has been a director since June 2020. He served on the Compensation Committee and Nominating and Governance Committee during 2023. 2023 Director Compensation shows $62,944 fees earned or paid in cash and $65,000 restricted stock unit awards, totaling $127,944. |
Data sourced from SEC filings. Last updated: 2026-03-05